<?xml version='1.0' encoding='utf-8'?>
<document id="24619889"><sentence text="Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations."><entity charOffset="35-50" id="DDI-PubMed.24619889.s1.e0" text="5-hydroxymethyl" /><entity charOffset="65-76" id="DDI-PubMed.24619889.s1.e1" text="tolterodine" /><entity charOffset="101-113" id="DDI-PubMed.24619889.s1.e2" text="fesoterodine" /><pair ddi="false" e1="DDI-PubMed.24619889.s1.e0" e2="DDI-PubMed.24619889.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24619889.s1.e0" e2="DDI-PubMed.24619889.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24619889.s1.e0" e2="DDI-PubMed.24619889.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24619889.s1.e1" e2="DDI-PubMed.24619889.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24619889.s1.e1" e2="DDI-PubMed.24619889.s1.e2" /></sentence><sentence text="This analysis was conducted to investigate factors that affect 5-hydroxymethyl tolterodine (5-HMT) pharmacokinetics after administration of fesoterodine sustained release tablets to Westerners and East Asians"><entity charOffset="63-90" id="DDI-PubMed.24619889.s2.e0" text="5-hydroxymethyl tolterodine" /><entity charOffset="92-97" id="DDI-PubMed.24619889.s2.e1" text="5-HMT" /><entity charOffset="140-152" id="DDI-PubMed.24619889.s2.e2" text="fesoterodine" /><pair ddi="false" e1="DDI-PubMed.24619889.s2.e0" e2="DDI-PubMed.24619889.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24619889.s2.e0" e2="DDI-PubMed.24619889.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24619889.s2.e0" e2="DDI-PubMed.24619889.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24619889.s2.e1" e2="DDI-PubMed.24619889.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24619889.s2.e1" e2="DDI-PubMed.24619889.s2.e2" /></sentence><sentence text=" Ten pharmacokinetic studies and three efficacy/safety studies in overactive bladder (OAB) patients were pooled for the population pharmacokinetic analysis" /><sentence text=" The plasma 5-HMT concentration data were described by a 1-compartment model with first order absorption and a lag time"><entity charOffset="12-23" id="DDI-PubMed.24619889.s4.e0" text="5-HMT" /></sentence><sentence text=" Creatinine clearance (CLCR), hepatic impairment, CYP2D6 genotype, and concomitant medication with CYP3A inhibitor/inducer were identified as influential covariates"><entity charOffset="1-11" id="DDI-PubMed.24619889.s5.e0" text="Creatinine" /></sentence><sentence text=" It was estimated that decreasing of CLCR from 80 to 15â€‰mL/min resulted in a 39" /><sentence text="5% reduction in 5-HMT apparent oral clearance (CL/F)"><entity charOffset="16-25" id="DDI-PubMed.24619889.s7.e0" text="5-HMT" /></sentence><sentence text=" Hepatic impairment, CYP2D6 poor metabolizer, and CYP3A inhibitor were estimated to reduce CL/F by about 60%, 40%, and 50%, respectively" /><sentence text=" CYP3A inducer resulted in about fourfold increase in CL/F" /><sentence text=" Although sex and Japanese ethnicity were selected as covariates on CL/F, each resulted in only about 10% decrease and increase of CL/F, respectively" /><sentence text=" Of the influential covariates of 5-HMT CL/F, CLCR, hepatic impairment, CYP2D6 genotype, and concomitant medication with CYP3A inhibitor/inducer were of significance, whereas sex and Japanese ethnicity covariates were considered not to have clinically significant impact on exposures of 5-HMT"><entity charOffset="34-38" id="DDI-PubMed.24619889.s11.e0" text="5-HMT" /><entity charOffset="287-291" id="DDI-PubMed.24619889.s11.e1" text="5-HMT" /><pair ddi="false" e1="DDI-PubMed.24619889.s11.e0" e2="DDI-PubMed.24619889.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24619889.s11.e0" e2="DDI-PubMed.24619889.s11.e1" /></sentence><sentence text=" " /></document>